Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pivotal ALCANZA Trial Secures Adcetris' Position in Cutaneous Lymphoma

Executive Summary

Regarding FDA filing in new CTCL indication in 2017, Seattle Genetics is hoping for a label that covers all patients, regardless of positivity for CD30, though the Phase III ALCANZA study was done in biomarker expressers.

You may also be interested in...



Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma

The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.

Ten Approvals To Look Out For In Q4

From AstraZeneca’s benralizumab in asthma to Kite Pharma’s CAR-T therapy, Scrip takes a look at some of the more interesting drug approvals expected by the end of the year, with the help of analysts from Informa's Biomedtracker.

Keeping Track: Oncology Stays Hot With Besponsa And Lynparza Approvals; New Uses Of Adcetris, Cabometyx Submitted

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097828

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel